Published in Health Business Week, December 9th, 2005
The net income on a GAAP basis for the quarter was $11.8 million or $0.13 per share as compared to a net loss of $14.3 million or $0.16 per share for the quarter ended September 30, 2004.
Alkermes reported a profitable quarter, driven by an increase in total revenues, which included the recognition of net collaborative profit related to work performed on the Vivitrex (naltrexone long-acting injection) program, the receipt of a milestone payment of $9 million from Eli Lilly and Company (Lilly) in conjunction with the initiation of the phase III...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.